jRCT2061240089招募中不适用
Post-marketing clinical study of AVIGAN tablets 200mg - Severe Fever with Thrombocytopenia Syndrome -
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 50
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 80age old not（—）
- 性别
- All
入选标准
- •(1) Patients reported to be positive for SFTSV in an RT-PCR test
- •(2) Patients within 7 days of the onset of symptoms (Fever, fatigue, headache, etc.) at the start of study treatment
- •(3) Age: >= 18 to < 80 years old (at the time of consent)
- •(4) Sex: Irrespective
- •(5) Outpatient/hospitalization: Hospitalization
- •(6) Patients from whom written informed consent can be obtained from the patients themselves.
排除标准
- •(1) Patients suspected of having concurrent serious bacterial infection, as indicated by increased procalcitonin levels, increased C-reactive protein levels, positive blood cultures before the start of Avigan tablets administration.
- •(2) Patients suspected of having concurrent serious fungal infection, as indicated by abnormal (1,3)-beta-D-glucan levels before the start of Avigan tablets administration.
- •(3) Patients tested positive for SARS-CoV-2 or influenza virus by nucleic acid detection test or antigen test using airway sample before the start of Avigan tablets administration.
- •(4) Patients with life-threatening serious complications, as indicated by cardiac dysfunction/Myocarditis, Rhabdomyolysis before the start of Avigan tablets administration.
- •(5) Patients with complications of an immunodeficiency disorder, such as acquired immunodeficiency syndrome (AIDS), or patients using immunosuppressants (excluding adrenocorticosteroids)
- •(6) Patients with severe renal impairment (CLcr < 30 mL/min) or for whom dialysis is performed regularly CLcr estimated value (mL/min) will be calculated using Cockcroft-Gault formula.
- •Male: [(140 - age in years) x body weight (kg)] / [72 x serum creatinine (mg/dL)]
- •Female: [0.85 x (140 - age in years) x body weight (kg)] / [72 x serum creatinine (mg/dL)]
- •(7) Patients with severe hepatic dysfunction (equivalent to Grade C in the Child-Pugh classification)
- •(8) Patients with advanced or terminal cancer who may not complete post-marketing clinical trials.
- •(9) Patients with a tendency for improvement in symptoms before the start of Avigan tablets administration.
- •(10) Patients for whom oral administration of favipiravir with tablet is difficult, as indicated by consciousness disturbed (score 3 or more of Score classification by clinical symptoms and findings before the start of Avigan tablets administration.
- •(11) Patients who have already been administered Avigan tablets for this episode of SFTS
- •(12) Patients who are pregnant or possibly pregnant
- •(13) Patients tested positive for pregnancy before the start of Avigan tablets administration.
- •(14) Lactating patients
- •(15) Patients who find it difficult to use effective contraceptive method (such as condoms,oral contraceptives, intrauterine systems (IUS), intrauterine devices (IUD), etc.) with their partner during the Avigan tablet administration periods and for 10 days after discontrinuation.
- •(16) Patients with a history of gout or patients who are currently being treated for gout or hyperuricemia
- •(17) Patients with hereditary xanthinuria
- •(18) Patients who have been diagnosed with hypouricemia (less than 1 mg/dL) or xanthine urinary calculus
- •(19) Patients deemed ineligible by the attending or collaborating physicians due to difficulties with frequent blood sampling or other reasons.
结局指标
主要结局
-
SFTSV genome load
次要结局
- Clinical symptoms and findings
研究者
相似试验
招募中
不适用
Post-Market Clinical Follow-up Study to the AGILON® Shoulder SystemKCT0007616Implantcast Asia100
未知
4 期
Postmarketing clinical study on AG-1749-clinical study on non-erosive reflux diseaseon-erosive reflux diseaseJPRN-jRCT1080221028Takeda Pharmaceutical Company Limited
未知
4 期
Post-marketing clinical study of Topina tabletsPartial epilepsyJPRN-jRCT1080220856Kyowa Hakko Kirin Co., Ltd.180
招募中
不适用
Post Market Clinical Follow-up Study for the Amvia/Solvia Pacemaker FamilyBradyardiaslow heart rate10007521NL-OMON56135BIOTRONIK SE and Co.KG30
未知
4 期
Post-marketing Clinical Study of Onglyza TabletJPRN-jRCT1080222299Kyowa Hakko Kirin Co., Ltd.